Gamco Investors INC. ET AL Purchases 42,100 Shares of GRAIL, Inc. $GRAL

Gamco Investors INC. ET AL increased its position in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 170.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,758 shares of the company's stock after acquiring an additional 42,100 shares during the quarter. Gamco Investors INC. ET AL owned about 0.16% of GRAIL worth $3,450,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. raised its holdings in GRAIL by 53.0% during the 1st quarter. Sei Investments Co. now owns 12,092 shares of the company's stock worth $625,000 after purchasing an additional 4,191 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of GRAIL by 3.5% in the 1st quarter. First Trust Advisors LP now owns 112,122 shares of the company's stock valued at $5,794,000 after purchasing an additional 3,797 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of GRAIL by 8.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,617 shares of the company's stock valued at $497,000 after purchasing an additional 772 shares during the last quarter. DUTCH ASSET Corp grew its position in shares of GRAIL by 14.8% during the 1st quarter. DUTCH ASSET Corp now owns 7,135 shares of the company's stock worth $369,000 after buying an additional 919 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of GRAIL by 88.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 408,650 shares of the company's stock worth $21,104,000 after buying an additional 191,857 shares during the period.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Several law firms reminded investors that August 4, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who purchased GRAIL securities from May 13, 2025, through February 19, 2026. These notices are procedural and do not establish that GRAIL or its executives violated securities laws. GRAL Shareholder Alert: August 4, 2026 Lead Plaintiff Deadline
• Negative Sentiment: Bronstein, Gewirtz & Grossman announced that a securities class action has been filed against GRAIL, Inc. (GRAL) and certain officers, seeking damages for alleged federal securities-law violations during the stated class period. The allegations add potential litigation costs, reputational risk and uncertainty for shareholders. GRAIL Investor Class Action Announcement
• Negative Sentiment: Additional firms, including Hagens Berman, Faruqi & Faruqi, Bleichmar Fonti & Auld, DJS Law Group and Robbins Geller, promoted the same or related litigation after the reported NHS-Galleri trial setback and sharp stock decline. The volume of announcements reinforces near-term legal overhang and may weigh on investor sentiment, although the notices largely repeat existing allegations rather than disclose new operating results. GRAIL Lawsuit Notice After Stock Drop

GRAIL Price Performance

GRAIL stock opened at $66.77 on Tuesday. The company's 50 day simple moving average is $66.67 and its 200 day simple moving average is $68.31. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -6.44 and a beta of 3.22.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, analysts predict that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GRAL. Wall Street Zen upgraded shares of GRAIL from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. TD Cowen reiterated a "buy" rating on shares of GRAIL in a research report on Wednesday, July 15th. Guggenheim cut their price target on GRAIL from $130.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Robert W. Baird set a $70.00 price target on GRAIL in a research report on Wednesday, May 6th. Finally, Piper Sandler raised their price target on GRAIL from $54.00 to $56.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $67.78.

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company's stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.83% of the stock is owned by company insiders.

GRAIL Profile

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.